|
CNU becomes the first U.S. health sciences university to integrate a reasoning-first adaptive AI system into its College of Pharmacy curriculum
NEWPORT BEACH, Calif. and ELK GROVE, Calif., March 11, 2026 /PRNewswire/ -- MindHYVE.ai™, Inc. and California Northstate University (CNU) have signed a Strategic Collaboration Framework (SCF) to deploy ArthurAI™, MindHYVE's Agentic Learning OS, within CNU's College of Pharmacy. The collaboration makes CNU the first health sciences university in the United States to integrate a reasoning-first agentic AI platform into its academic curriculum.
The global AI education market, valued at $7.57 billion in 2025 and projected to exceed $112 billion by 2034, has yet to produce a reasoning-first platform purpose-built for health sciences. While leading research universities—including Harvard, Stanford, MIT, and Oxford—continue to develop institutional policies governing student use of generative AI tools, CNU's partnership with MindHYVE.ai™ moves beyond policy into deployment. Rather than treating AI as a content tool to be regulated, ArthurAI™ functions as an adaptive reasoning system that learns each student's cognitive profile and adjusts instructional delivery in real time, while maintaining full FERPA compliance and transparent audit trails.
A key advantage of the ArthurAI™ platform is its AI-powered curriculum design and delivery system. Using agentic capabilities, ArthurAI™ ingests an institution's existing curriculum and generates modernized, refreshed course content that prepares students for careers in the rapidly approaching era of AI-powered pharmacology—future-proofing graduates for a profession being reshaped by artificial intelligence and equipping them with the fluency to lead in a new AI economy.
Under the framework, MindHYVE.ai™ will deliver a customized ArthurAI™ deployment aligned to CNU-identified courses requiring advanced reasoning and conceptual mastery. Initial implementation will focus on high-cognitive-load pharmacy courses, with a pathway for broader adoption across CNU's programs in medicine, dentistry, psychology, and nursing through:
- ArthurAI™ University Learning Edition (ULE) — AI-powered curriculum intelligence that transforms existing degree programs into adaptive, competency-driven learning experiences with real-time cognitive profiling for every enrolled student
- ArthurAI™ Corporate Learning Edition (CLE) — a structured AI upskilling program for faculty and institutional staff, delivered in partnership with the California Institute of Artificial Intelligence (CIAI) to build organization-wide AI fluency and literacy
- The Dawn Directive™ — CIAI's flagship 4-month, 18-course, 360-hour AI fluency certification program, powered by MindHYVE™'s ArthurAI™ VLE Agentic Learning OS
The ArthurAI™ deployment extends a growing relationship between CNU and MindHYVE.ai™. The two organizations have also established a collaboration framework around ChironAI™, MindHYVE's clinical decision support platform, to explore pharmacogenomics applications within CNU's College of Pharmacy. With CNU currently constructing a teaching hospital, the partnership positions both organizations to advance an integrated education-to-clinical intelligence pipeline—from AI-powered learning in the classroom to AI-assisted decision-making at the point of care.
CNU joins a growing portfolio of institutional deployments for MindHYVE.ai™, which currently operates across 15+ countries with partnerships spanning education, healthcare, and governance.
"The real challenge facing pharmacy education isn't access to information—anyone can look that up. It's that AI is already doing what we've traditionally trained pharmacists to do. Drug interaction checks, dosing calculations, formulary management—machines handle that now. The industry doesn't need more pharmacists educated the old way. It needs AI-powered pharmacists who can lead a profession that's being fundamentally transformed. ArthurAI™ doesn't just teach pharmacy—it produces the pharmacist of the future."
— Bill Faruki, Founder and CEO, MindHYVE.ai™
"Every health sciences institution will face a decision: adapt to AI or fall behind. CNU is not waiting. We partnered with MindHYVE.ai™ because the pharmacists and clinicians we graduate must be as fluent in artificial intelligence as they are in pharmacology. This isn't an experiment—it's the future of health sciences education, and we intend to define it."
— Dr. Alvin Cheung, President and CEO, California Northstate University
"The Dawn Directive was built to produce AI-fluent professionals across every industry. Deploying it inside a College of Pharmacy proves that this certification framework transfers to any regulated discipline—and that the demand for AI fluency in healthcare is no longer theoretical."
— California Institute of Artificial Intelligence (CIAI)
About California Northstate University
California Northstate University is a private, health-sciences-focused institution based in Northern California offering programs in medicine, pharmacy, dentistry, psychology, nursing, and health sciences. CNU is committed to advancing education, research, and service in healthcare.
About MindHYVE.ai™
MindHYVE.ai™ engineers domain-specific agentic AI systems for education, healthcare, law, finance, and governance. Its technology stack is powered by Eve-Fusion™, a proprietary multi-model consensus reasoning engine, and deployed on Eve-Grid™, MindHYVE's enterprise-grade Azure-native cloud infrastructure. The company operates eleven Digital Employees—domain-specific AI agents including ArthurAI™ for adaptive learning and ChironAI™ for clinical decision support—with deployments spanning North America, Asia, and Africa. MindHYVE does not use client data for model training; all training relies exclusively on synthetically generated data through Eve-Genesis™, its proprietary reasoning training framework.
For more information:
Website: www.mindhyve.ai | Email: hello@mindhyve.ai | Phone: +1 (949) 200-8668
Partnership & Investment Inquiries:
James Barry | james.barry@mindhyve.io
Media Contact:
Marc Ortiz | marc.ortiz@mindhyve.io
CNU becomes the first U.S. health sciences university to integrate a reasoning-first adaptive AI system into its College of Pharmacy curriculum
NEWPORT BEACH, Calif. and ELK GROVE, Calif., March 11, 2026 /PRNewswire/ -- MindHYVE.ai™, Inc. and California Northstate University (CNU) have signed a Strategic Collaboration Framework (SCF) to deploy ArthurAI™, MindHYVE's Agentic Learning OS, within CNU's College of Pharmacy. The collaboration makes CNU the first health sciences university in the United States to integrate a reasoning-first agentic AI platform into its academic curriculum.
The global AI education market, valued at $7.57 billion in 2025 and projected to exceed $112 billion by 2034, has yet to produce a reasoning-first platform purpose-built for health sciences. While leading research universities—including Harvard, Stanford, MIT, and Oxford—continue to develop institutional policies governing student use of generative AI tools, CNU's partnership with MindHYVE.ai™ moves beyond policy into deployment. Rather than treating AI as a content tool to be regulated, ArthurAI™ functions as an adaptive reasoning system that learns each student's cognitive profile and adjusts instructional delivery in real time, while maintaining full FERPA compliance and transparent audit trails.
A key advantage of the ArthurAI™ platform is its AI-powered curriculum design and delivery system. Using agentic capabilities, ArthurAI™ ingests an institution's existing curriculum and generates modernized, refreshed course content that prepares students for careers in the rapidly approaching era of AI-powered pharmacology—future-proofing graduates for a profession being reshaped by artificial intelligence and equipping them with the fluency to lead in a new AI economy.
Under the framework, MindHYVE.ai™ will deliver a customized ArthurAI™ deployment aligned to CNU-identified courses requiring advanced reasoning and conceptual mastery. Initial implementation will focus on high-cognitive-load pharmacy courses, with a pathway for broader adoption across CNU's programs in medicine, dentistry, psychology, and nursing through:
- ArthurAI™ University Learning Edition (ULE) — AI-powered curriculum intelligence that transforms existing degree programs into adaptive, competency-driven learning experiences with real-time cognitive profiling for every enrolled student
- ArthurAI™ Corporate Learning Edition (CLE) — a structured AI upskilling program for faculty and institutional staff, delivered in partnership with the California Institute of Artificial Intelligence (CIAI) to build organization-wide AI fluency and literacy
- The Dawn Directive™ — CIAI's flagship 4-month, 18-course, 360-hour AI fluency certification program, powered by MindHYVE™'s ArthurAI™ VLE Agentic Learning OS
The ArthurAI™ deployment extends a growing relationship between CNU and MindHYVE.ai™. The two organizations have also established a collaboration framework around ChironAI™, MindHYVE's clinical decision support platform, to explore pharmacogenomics applications within CNU's College of Pharmacy. With CNU currently constructing a teaching hospital, the partnership positions both organizations to advance an integrated education-to-clinical intelligence pipeline—from AI-powered learning in the classroom to AI-assisted decision-making at the point of care.
CNU joins a growing portfolio of institutional deployments for MindHYVE.ai™, which currently operates across 15+ countries with partnerships spanning education, healthcare, and governance.
"The real challenge facing pharmacy education isn't access to information—anyone can look that up. It's that AI is already doing what we've traditionally trained pharmacists to do. Drug interaction checks, dosing calculations, formulary management—machines handle that now. The industry doesn't need more pharmacists educated the old way. It needs AI-powered pharmacists who can lead a profession that's being fundamentally transformed. ArthurAI™ doesn't just teach pharmacy—it produces the pharmacist of the future."
— Bill Faruki, Founder and CEO, MindHYVE.ai™
"Every health sciences institution will face a decision: adapt to AI or fall behind. CNU is not waiting. We partnered with MindHYVE.ai™ because the pharmacists and clinicians we graduate must be as fluent in artificial intelligence as they are in pharmacology. This isn't an experiment—it's the future of health sciences education, and we intend to define it."
— Dr. Alvin Cheung, President and CEO, California Northstate University
"The Dawn Directive was built to produce AI-fluent professionals across every industry. Deploying it inside a College of Pharmacy proves that this certification framework transfers to any regulated discipline—and that the demand for AI fluency in healthcare is no longer theoretical."
— California Institute of Artificial Intelligence (CIAI)
About California Northstate University
California Northstate University is a private, health-sciences-focused institution based in Northern California offering programs in medicine, pharmacy, dentistry, psychology, nursing, and health sciences. CNU is committed to advancing education, research, and service in healthcare.
About MindHYVE.ai™
MindHYVE.ai™ engineers domain-specific agentic AI systems for education, healthcare, law, finance, and governance. Its technology stack is powered by Eve-Fusion™, a proprietary multi-model consensus reasoning engine, and deployed on Eve-Grid™, MindHYVE's enterprise-grade Azure-native cloud infrastructure. The company operates eleven Digital Employees—domain-specific AI agents including ArthurAI™ for adaptive learning and ChironAI™ for clinical decision support—with deployments spanning North America, Asia, and Africa. MindHYVE does not use client data for model training; all training relies exclusively on synthetically generated data through Eve-Genesis™, its proprietary reasoning training framework.
For more information:
Website: www.mindhyve.ai | Email: hello@mindhyve.ai | Phone: +1 (949) 200-8668
Partnership & Investment Inquiries:
James Barry | james.barry@mindhyve.io
Media Contact:
Marc Ortiz | marc.ortiz@mindhyve.io
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MindHYVE.ai™ and California Northstate University Deploy First Agentic AI Learning Platform in U.S. Health Sciences Education
KUALA LUMPUR, Malaysia, March 12, 2026 /PRNewswire/ -- As Malaysia commemorates National Rare Disease Day and marks the launch of the National Policy for Rare Diseases, long-term, sustainable care for individuals living with rare, complex genetic conditions is now gaining growing attention and interest from across public and private stakeholders.
Among the critical components of long-term care for certain rare genetic metabolic disorders is specialised nutrition, which is often a therapeutic necessity, rather than a dietary or lifestyle preference for many patients.
For individuals diagnosed with inborn errors of metabolism (IEM), strict dietary management forms part of lifelong treatment. These patients often require carefully calibrated specialised nutritional formulations to prevent metabolic complications, as these conditions could impair the body's ability to process certain nutrients.
Therefore, securing stable, reliable access to specialised nutrition is vital for more resilient care management of rare disease patients.
When Nutrition Becomes Essential Support
Unlike conventional dietary support, specialised nutrition for rare metabolic diseases is designed to meet highly specific biochemical requirements. Even minor disruptions in availability can affect disease management, particularly for paediatric patients whose growth and neurological development depend on precise dietary control.
According to Dr Ngu Lock Hock, Clinical Genetics Consultant and Head of the Genetics Department of Hospital Kuala Lumpur, patients with genetic metabolic disorders in Malaysia have historically depended heavily on imported specialised nutrition products.
"Many metabolic formulas and specialised dietary substitutes were sourced from overseas manufacturers. While they provided clinically necessary support, dependence on imports meant exposure to both supply vulnerabilities and higher costs," he said.
Imported formulations are often subject to currency fluctuations, transportation expenses, and international production constraints, and geopolitical tensions, all of which can contribute to an increased financial burden for families and healthcare institutions.
In addition, disruptions in global manufacturing or shipping logistics could further create uncertainty for caregivers managing lifelong conditions, complicating long-term care planning and continuity of support.
"In metabolic care, consistency is critical. Any interruption in access to specialised nutrition, whether due to supply delays or affordability challenges, creates stress for caregivers and potential clinical risk for patients," he added.
Addressing Supply Vulnerability and Building Local Production Capacity
Malaysia's reliance on imported specialised metabolic nutrition has reflected global patterns, where specialised formulations are often concentrated among a small number of international producers.
However, recent global supply chain disruptions have highlighted the need for stronger domestic resilience in essential healthcare components. While pharmaceutical supply security is frequently discussed, specialised nutrition, particularly for rare genetic metabolic disorders, remains much less visible in healthcare ecosystem resilience conversations.
The recently launched National Policy for Rare Diseases in Malaysia now provides a structured roadmap for strengthening Malaysia's rare disease healthcare ecosystem, including improving access to essential services and long-term support. Within this context, building local production capacity in specialised metabolic nutrition represents an essential area of system reinforcement.
In response to this, local production initiatives have begun to take shape among homegrown healthcare solutions providers to develop locally produced specialised nutrition solutions tailored for genetic metabolic disorders. Among them are protein-free specialised nutrition products manufactured in Malaysia under VALENS, a specialised nutrition brand by homegrown pharmaceutical and consumer health company Pharm-D Health Science.
Such local production initiatives aim to complement existing imported options by reducing dependence on singular foreign supply chains and improving domestic responsiveness to clinical needs, as local production can shorten supply timelines, enhance distribution stability, and allow closer collaboration between manufacturers and healthcare providers managing rare genetic metabolic conditions in Malaysia.
Industry observers note that strengthening domestic capability does not replace international innovation but rather creates a more balanced and resilient healthcare ecosystem for rare disease patients.
Supporting Long-Term Sustainability
For families living with rare genetic metabolic disorders, care management extends beyond hospital settings into daily life. Parents and caregivers meticulously monitor dietary intake, calculate nutrient allowances, and maintain strict adherence to prescribed nutritional regimens.
More stable access to specialised nutrition, therefore, plays a direct role in maintaining clinical stability and quality of life.
As Malaysia advances its rare disease agenda, reinforcing continuity of specialised nutrition supply aligns with broader goals of healthcare sustainability and system resilience.
Dr Ngu emphasised that multi-stakeholder collaboration remains central to this progress.
"Policy direction, clinical expertise, patient advocacy and responsible industry participation must work together to strengthen rare disease care. Building sustainable access to specialised nutrition is part of that collective responsibility," he said.
Towards a More Resilient Rare Disease Ecosystem
As Malaysia advances its rare disease healthcare agenda, experts emphasise that healthcare resilience must extend beyond pharmaceuticals and include other essential care components, such as specialised nutrition.
Strengthening domestic production capability in specialised nutrition, therefore, represents a much-needed practical step toward reinforcing that commitment.
As local capability continues to develop alongside global partnerships, Malaysia's rare disease healthcare ecosystem stands to benefit from greater stability, responsiveness, and preparedness, which in turn supports Malaysian patients and families of the rare disease community.
About Pharm-D Health Science (PDHS)
Founded in 2001, Pharm-D Health Science (PDHS) is a pharmaceutical and consumer health company specialising in specialised medicines, pharmaceuticals, healthcare and consumer health products. With a steadfast commitment to pioneering research, development, and manufacturing, PDHS offers a comprehensive array of solutions, including medications, over-the-counter medications, specialised nutrition, health supplements, and medical devices. Notably, PDHS is also a pioneer in postbiotics research and supply in Malaysia.
Beyond pharmaceuticals, the company provides healthcare and consumer health solutions under trusted house brands such as VALENS, ELDON, Lang Bragman, MedSkin, Reflux-G, Retane, and more. Ultimately, Pharm-D Health Science's dedication to scientific excellence and holistic healthcare is driven by the mission to make health and wellbeing accessible for all with science.
For more information about Pharm-D Health Science, please visit https://www.pharmdhs.com/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Building Resilient Rare Disease Support in Malaysia with Pharm-D Health Science's VALENS Specialised Nutrition
